Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenal Hyperplasia, Congenital | 4 | 2021 | 33 | 0.990 |
Why?
|
| Hydrocortisone | 3 | 2021 | 219 | 0.700 |
Why?
|
| Glucocorticoids | 3 | 2021 | 385 | 0.620 |
Why?
|
| Menarche | 1 | 2014 | 35 | 0.460 |
Why?
|
| Puberty, Precocious | 1 | 2014 | 29 | 0.460 |
Why?
|
| Uterine Hemorrhage | 1 | 2014 | 43 | 0.460 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2014 | 4 | 0.460 |
Why?
|
| Cushing Syndrome | 1 | 2014 | 17 | 0.450 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 196 | 0.450 |
Why?
|
| Quinazolines | 1 | 2014 | 176 | 0.410 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 212 | 0.410 |
Why?
|
| Piperidines | 1 | 2014 | 205 | 0.400 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 154 | 0.400 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 199 | 0.370 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2008 | 93 | 0.210 |
Why?
|
| Muscular Diseases | 3 | 2008 | 103 | 0.210 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2008 | 134 | 0.210 |
Why?
|
| Oxidative Stress | 5 | 2013 | 807 | 0.200 |
Why?
|
| Polyadenylation | 1 | 2023 | 55 | 0.200 |
Why?
|
| Mitochondria, Muscle | 4 | 2008 | 35 | 0.180 |
Why?
|
| Puberty | 1 | 2021 | 95 | 0.180 |
Why?
|
| Steroids | 1 | 2021 | 203 | 0.180 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2013 | 97 | 0.170 |
Why?
|
| Zebrafish | 1 | 2023 | 388 | 0.170 |
Why?
|
| Muscle, Skeletal | 4 | 2008 | 953 | 0.150 |
Why?
|
| Circadian Rhythm | 2 | 2021 | 274 | 0.150 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2015 | 76 | 0.140 |
Why?
|
| Appetite Regulation | 1 | 2017 | 41 | 0.140 |
Why?
|
| Adipose Tissue, Brown | 1 | 2017 | 82 | 0.140 |
Why?
|
| Infusions, Subcutaneous | 1 | 2016 | 7 | 0.140 |
Why?
|
| Neuropeptides | 1 | 2017 | 114 | 0.130 |
Why?
|
| Biomarkers | 4 | 2021 | 3066 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2021 | 647 | 0.130 |
Why?
|
| Diabetes Insipidus, Nephrogenic | 1 | 2016 | 1 | 0.130 |
Why?
|
| Receptors, Vasopressin | 1 | 2016 | 11 | 0.130 |
Why?
|
| Bone Density | 2 | 2018 | 320 | 0.130 |
Why?
|
| RNA Splice Sites | 1 | 2016 | 87 | 0.120 |
Why?
|
| Growth and Development | 1 | 2015 | 22 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 215 | 0.120 |
Why?
|
| Siblings | 1 | 2016 | 196 | 0.120 |
Why?
|
| Hormones | 1 | 2015 | 187 | 0.120 |
Why?
|
| Wrist | 1 | 2014 | 24 | 0.120 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2014 | 40 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 58 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 72 | 0.110 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2014 | 34 | 0.110 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2014 | 58 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2015 | 867 | 0.100 |
Why?
|
| Cholecalciferol | 1 | 2012 | 22 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 829 | 0.100 |
Why?
|
| Male | 11 | 2021 | 61356 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1274 | 0.090 |
Why?
|
| Humans | 18 | 2023 | 124907 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 290 | 0.080 |
Why?
|
| Female | 10 | 2021 | 66625 | 0.080 |
Why?
|
| Young Adult | 3 | 2021 | 8999 | 0.080 |
Why?
|
| 3' Untranslated Regions | 2 | 2023 | 165 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2015 | 841 | 0.070 |
Why?
|
| Mitochondrial Myopathies | 1 | 2007 | 28 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2021 | 1570 | 0.070 |
Why?
|
| Adult | 5 | 2021 | 29499 | 0.070 |
Why?
|
| Energy Metabolism | 2 | 2008 | 778 | 0.060 |
Why?
|
| Adolescent | 4 | 2021 | 19341 | 0.060 |
Why?
|
| Ischemia | 1 | 2008 | 357 | 0.060 |
Why?
|
| Asthma | 1 | 2012 | 744 | 0.060 |
Why?
|
| Child | 4 | 2021 | 24479 | 0.050 |
Why?
|
| Embryo, Nonmammalian | 1 | 2023 | 144 | 0.050 |
Why?
|
| Mutation | 1 | 2016 | 5815 | 0.050 |
Why?
|
| Introns | 1 | 2023 | 301 | 0.050 |
Why?
|
| Sulfates | 1 | 2021 | 35 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2021 | 16309 | 0.050 |
Why?
|
| Aldehydes | 2 | 2013 | 31 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2021 | 174 | 0.040 |
Why?
|
| Exons | 1 | 2023 | 796 | 0.040 |
Why?
|
| Aging | 2 | 2017 | 1189 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2014 | 14057 | 0.040 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 28 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2021 | 230 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2021 | 436 | 0.040 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2017 | 19 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2017 | 78 | 0.040 |
Why?
|
| Ghrelin | 1 | 2017 | 54 | 0.030 |
Why?
|
| Glucagon | 1 | 2017 | 185 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 161 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 142 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 386 | 0.030 |
Why?
|
| Pregnanediones | 1 | 2015 | 2 | 0.030 |
Why?
|
| 5-alpha-Dihydroprogesterone | 1 | 2015 | 2 | 0.030 |
Why?
|
| Androsterone | 1 | 2015 | 3 | 0.030 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2015 | 4 | 0.030 |
Why?
|
| Leptin | 1 | 2017 | 217 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 191 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2012 | 1193 | 0.030 |
Why?
|
| Androstenedione | 1 | 2015 | 11 | 0.030 |
Why?
|
| Animals | 5 | 2023 | 34209 | 0.030 |
Why?
|
| Dehydroepiandrosterone | 1 | 2015 | 18 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 300 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 275 | 0.030 |
Why?
|
| Body Composition | 1 | 2017 | 525 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 426 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2014 | 55 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2015 | 275 | 0.030 |
Why?
|
| Protein Carbonylation | 1 | 2013 | 7 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 791 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2013 | 42 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 4432 | 0.030 |
Why?
|
| Progesterone | 1 | 2015 | 625 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 240 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 701 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 753 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 1595 | 0.020 |
Why?
|
| Spirometry | 1 | 2012 | 74 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1019 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2015 | 1010 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 3100 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 160 | 0.020 |
Why?
|
| Seasons | 1 | 2012 | 311 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 1001 | 0.020 |
Why?
|
| Testosterone | 1 | 2015 | 538 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8197 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3882 | 0.020 |
Why?
|
| Myocardium | 1 | 2015 | 1008 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1948 | 0.020 |
Why?
|
| ATP Synthetase Complexes | 1 | 2008 | 1 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2826 | 0.020 |
Why?
|
| Citrate (si)-Synthase | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hindlimb | 1 | 2008 | 76 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1354 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 29 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 2008 | 44 | 0.020 |
Why?
|
| Electron Transport | 1 | 2007 | 55 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 2007 | 56 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 138 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1402 | 0.020 |
Why?
|
| Carnitine | 1 | 2007 | 75 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2008 | 103 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2007 | 108 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2007 | 396 | 0.020 |
Why?
|
| Lung | 1 | 2015 | 1488 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2007 | 76 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 10282 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2007 | 84 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3448 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3290 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2007 | 211 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 2052 | 0.020 |
Why?
|
| Middle Aged | 2 | 2017 | 26755 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2007 | 187 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2007 | 851 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5158 | 0.010 |
Why?
|
| Exercise | 1 | 2008 | 820 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 1792 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 12490 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 19712 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 2542 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 12355 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 17751 | 0.010 |
Why?
|